Kenneth J Warrington

List of Publications by Year
in descending order

197	8,813	47006	51608
papers	citations	47 h-index	86 g-index

220	220	220	6496
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis and Rheumatism, 2011, 63, 633-639.	6.7	425
2	T-Cellâ€“Mediated Lysis of Endothelial Cells in Acute Coronary Syndromes. Circulation, 2002, 105, 570-575.	1.6	332
3	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	5.6	271
4	Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Annals of the Rheumatic Diseases, 2013, 72, 1989-1994.	0.9	261
5	Large-vessel giant cell arteritis: a cohort study. Rheumatology, 2015, 54, 463-470.	1.9	245
6	Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein for the Diagnosis of Giant Cell Arteritis. Seminars in Arthritis and Rheumatism, 2012, 41, 866-871.	3.4	233
7	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Annals of the Rheumatic Diseases, 2012, 71, 1329-1334.	0.9	218
8	Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Annals of the Rheumatic Diseases, 2015, 74, 1072-1077.	0.9	216
9	CD4+,CD28? T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthritis and Rheumatism, 2001, 44, 13-20.	6.7	208
10	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E970-E979.	7.1	172
11	The Epidemiology of Antiphospholipid Syndrome: A Populationâ€Based Study. Arthritis and Rheumatology, 2019, 71, 1545-1552.	5.6	172
12	Diagnostic Features, Treatment, and Outcomes of Takayasu Arteritis in a US Cohort of 126 Patients. Mayo Clinic Proceedings, 2013, 88, 822-830.	3.0	161
13	Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 43-54.	6.7	160
14	Vasculitis Associated With Tumor Necrosis Factor-Î± Inhibitors. Mayo Clinic Proceedings, 2012, 87, 739-745.	3.0	159
15	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. RMD Open, 2018, 4, e000598.	3.8	155
16	Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Modern Pathology, 2017, 30, 788-796.	5.5	148
17	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	6.2	144
18	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. American Journal of Human Genetics, 2013, 93, 298-305.	6.2	143

#	Article	IF	Citations
19	Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology, 2018, 57, ii32-ii42.	1.9	136
20	Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology, 2016, 55, 347-356.	1.9	131
21	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4Ig) for the Treatment of Takayasu Arteritis. Arthritis and Rheumatology, 2017, 69, 846-853.	5.6	131
22	Blocking the NOTCH Pathway Inhibits Vascular Inflammation in Large-Vessel Vasculitis. Circulation, 2011, 123, 309-318.	1.6	130
23	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. Journal of Rheumatology, 2015, 42, 1213-1217.	2.0	129
24	Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Research and Therapy, 2005, 7, R984.	3.5	124
25	CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood, 2003, 101, 3543-3549.	1.4	121
26	Polymyalgia rheumatica. Lancet, The, 2013, 381, 63-72.	13.7	120
27	Visual Manifestations in Giant Cell Arteritis: Trend over 5 Decades in a Population-based Cohort. Journal of Rheumatology, 2015, 42, 309-315.	2.0	103
28	Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H813-H821.	3.2	100
29	A multicenter, randomized, doubleâ€blind, placeboâ€controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in lateâ€phase disease. Arthritis and Rheumatism, 2008, 58, 1810-1822.	6.7	99
30	Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. Ophthalmology, 2016, 123, 1999-2003.	5.2	97
31	Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology, 2014, 53, 890-899.	1.9	89
32	Noninfectious Ascending Aortitis: A Case Series of 64 Patients. Journal of Rheumatology, 2009, 36, 2290-2297.	2.0	83
33	Rheumatoid vasculitis. Current Opinion in Rheumatology, 2015, 27, 63-70.	4.3	83
34	Increase in age at onset of giant cell arteritis: a population-based study. Annals of the Rheumatic Diseases, 2010, 69, 780-781.	0.9	82
35	Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2015, 67, 1361-1368.	5.6	79
36	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78

#	Article	IF	Citations
37	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care and Research, 2020, 72, 1615-1624.	3.4	77
38	Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with longâ€term followup. Arthritis Care and Research, 2012, 64, 1079-1083.	3.4	76
39	The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950â€“2009. Scandinavian Journal of Rheumatology, 2015, 44, 215-218.	1.1	72
40	Symptomatic Lower Extremity Vasculitis in Giant Cell Arteritis: A Case Series. Journal of Rheumatology, 2009, 36, 2277-2283.	2.0	69
41	Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Current Opinion in Rheumatology, 2016, 28, 211-217.	4.3	64
42	Clinical Heterogeneity of the VEXAS Syndrome. Mayo Clinic Proceedings, 2021, 96, 2653-2659.	3.0	58
43	Polyarteritis Nodosa-like Vasculitis in Association with Minocycline Use: A Single-Center Case Series. Seminars in Arthritis and Rheumatism, 2012, 42, 213-221.	3.4	56
44	Localized vasculitis of the gastrointestinal tract: a case series. Rheumatology, 2010, 49, 1326-1335.	1.9	54
45	Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood, 2022, 140, 1496-1506.	1.4	54
46	Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they?. Seminars in Arthritis and Rheumatism, 2015, 44, 724-728.	3.4	53
47	Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis. Journal of Rheumatology, 2012, 39, 303-309.	2.0	51
48	Statin Use in Giant Cell Arteritis: A Retrospective Study. Journal of Rheumatology, 2013, 40, 910-915.	2.0	50
49	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. Journal of Rheumatology, 2018, 45, 1289-1295.	2.0	49
50	Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 653-661.	0.9	49
51	Retrospective Comparison of Open versus Endovascular Procedures for Takayasu Arteritis. Journal of Rheumatology, 2016, 43, 427-432.	2.0	48
52	Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis with Severe Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 2688-2704.	6.1	48
53	Cerebrovascular accident in patients with giant cell arteritis: A systematic review and meta-analysis of cohort studies. Seminars in Arthritis and Rheumatism, 2016, 46, 361-366.	3.4	47
54	Mitochondrial aspartate regulates TNF biogenesis and autoimmune tissue inflammation. Nature Immunology, 2021, 22, 1551-1562.	14.5	47

#	Article	IF	Citations
55	Coronary artery disease in giant cell arteritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2015, 44, 586-591.	3.4	44
56	Arterial lesions in giant cell arteritis: A longitudinal study. Seminars in Arthritis and Rheumatism, 2019, 48, 707-713.	3.4	43
57	Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series. Arthritis Care and Research, 2011, 63, 761-765.	3.4	41
58	Cardiovascular Risk and Acute Coronary Syndrome in Giant Cell Arteritis: A Populationâ€Based Retrospective Cohort Study. Arthritis Care and Research, 2015, 67, 396-402.	3.4	41
59	Gut microbial determinants of clinically important improvement in patients with rheumatoid arthritis. Genome Medicine, 2021, 13, 149.	8.2	41
60	Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets. Current Drug Targets, 2003, 4, 505-516.	2.1	41
61	Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets. BMC Rheumatology, 2017, 1, 2.	1.6	39
62	Polymyalgia Rheumatica and Giant Cell Arteritis in Older Patients. Drugs and Aging, 2011, 28, 651-666.	2.7	37
63	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. Journal of Rheumatology, 2016, 43, 1078-1084.	2.0	37
64	The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. BMC Musculoskeletal Disorders, 2016, 17, 363.	1.9	37
65	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Annals of the Rheumatic Diseases, 2022, 81, 861-867.	0.9	35
66	Malignancy risk in patients with giant cell arteritis: A populationâ€based cohort study. Arthritis Care and Research, 2010, 62, 149-154.	3.4	34
67	Sequenceâ€Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. Arthritis and Rheumatology, 2021, 73, 512-519.	5.6	34
68	NOTCH-induced rerouting of endosomal trafficking disables regulatory T cells in vasculitis. Journal of Clinical Investigation, 2021, 131, .	8.2	34
69	Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. Arthritis Research and Therapy, 2009, 11, R50.	3.5	33
70	Body mass index and the risk of giant cell arteritis–results from a prospective study. Rheumatology, 2015, 54, 433-440.	1.9	33
71	Clinical Spectrum of Mediumâ€Sized Vessel Vasculitis. Arthritis Care and Research, 2017, 69, 884-891.	3.4	33
72	Derivation of an angiographically based classification system in Takayasuâ€™s arteritis: an observational study from India and North America. Rheumatology, 2020, 59, 1118-1127.	1.9	33

#	Article	IF	Citations
73	Modulation of TNF-Î± Gene Expression by IFN-Î³ and Pamidronate in Murine Macrophages: Regulation by STAT1-Dependent Pathways. Journal of Immunology, 2005, 174, 1801-1810.	0.8	32
74	Assessment of the frequency of cardiovascular risk factors in patients with Takayasuâ€™s arteritis. Rheumatology, 2017, 56, 1939-1944.	1.9	32
75	Predictors of Dissection in Aortic Aneurysms From Giant Cell Arteritis. Journal of Clinical Rheumatology, 2016, 22, 184-187.	0.9	30
76	Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. Journal of Rheumatology, 2019, 46, 501-508.	2.0	30
77	Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. Rheumatology, 2020, 59, 3229-3236.	1.9	30
78	Evaluation of damage in giant cell arteritis. Rheumatology, 2018, 57, 322-328.	1.9	28
79	Malignancy Risk in Vasculitis. Therapeutic Advances in Musculoskeletal Disease, 2011, 3, 55-63.	2.7	27
80	Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritisâ€associated interstitial lung disease and idiopathic pulmonary fibrosis. FASEB Journal, 2022, 36, e22336.	0.5	27
81	Aseptic meningitis in adult onset Stillâ€™s disease. Rheumatology International, 2012, 32, 4031-4034.	3.0	26
82	Clinical Characteristics of Biopsy-Proven IgA Vasculitis in Children and Adults: AÂRetrospective Cohort Study. Mayo Clinic Proceedings, 2019, 94, 1769-1780.	3.0	26
83	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	6.2	26
84	Lower extremity vasculitis in polymyalgia rheumatica and giant cell arteritis. Current Opinion in Rheumatology, 2011, 23, 38-42.	4.3	25
85	Patients with giant cell arteritis have a lower prevalence of diabetes mellitus: A systematic review and meta-analysis. Modern Rheumatology, 2016, 26, 410-414.	1.8	25
86	Spectrum of Aortic Disease in the Giant Cell Arteritis Population. American Journal of Cardiology, 2018, 121, 501-508.	1.6	25
87	Patterns of clinical presentation in Takayasu's arteritis. Seminars in Arthritis and Rheumatism, 2020, 50, 576-581.	3.4	25
88	Vasculitis of the Gastrointestinal Tract in Chronic Periaortitis. Medicine (United States), 2011, 90, 28-39.	1.0	24
89	Arterial involvement in Erdheimâ€“Chester disease. Medicine (United States), 2018, 97, e13452.	1.0	24
90	Cancer preceding giant cell arteritis: A caseâ€“control study. Arthritis and Rheumatism, 2010, 62, 1763-1769.	6.7	23

#	Article	IF	Citations
91	Concurrent Takayasu Arteritis With Common Variable Immunodeficiency and Moyamoya Disease. Annals of Vascular Surgery, 2013, 27, 240.e13-240.e18.	0.9	23
92	Largeâ€Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease?. Arthritis Care and Research, 2018, 70, 1406-1411.	3.4	23
93	Characterisation of the immune response to type I collagen in scleroderma. Arthritis Research and Therapy, 2006, 8, R136.	3.5	21
94	Surgical management of ascending aortic aneurysm due to non-infectious aortitis. Scandinavian Cardiovascular Journal, 2008, 42, 417-424.	1.2	21
95	Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica. Therapeutic Advances in Musculoskeletal Disease, 2014, 6, 8-19.	2.7	21
96	Classification of large vessel vasculitis: Can we separate giant cell arteritis from Takayasu arteritis?. Presse Medicale, 2017, 46, e205-e213.	1.9	21
97	Clinical Manifestations and Longâ€Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. ACR Open Rheumatology, 2021, 3, 404-412.	2.1	21
98	Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity. Arthritis Research and Therapy, 2021, 23, 164.	3.5	21
99	VEXAS within the spectrum of rheumatologic disease. Seminars in Hematology, 2021, 58, 218-225.	3.4	21
100	Evaluation for Clinical Predictors of Positive Temporal Artery Biopsy in Giant Cell Arteritis. Journal of Oral and Maxillofacial Surgery, 2011, 69, 36-40.	1.2	19
101	Recent Advances in Diagnostic Strategies for Giant Cell Arteritis. Current Neurology and Neuroscience Reports, 2012, 12, 138-144.	4.2	19
102	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. Frontiers in Immunology, 2022, 13, 834981.	4.8	19
103	Delayed Diagnosis of Biopsy-Negative Giant Cell Arteritis Presenting as Fever of Unknown Origin. Journal of General Internal Medicine, 2009, 24, 532-536.	2.6	18
104	Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study. PLoS ONE, 2016, 11, e0149579.	2.5	18
105	Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis. Clinical Rheumatology, 2016, 35, 2741-2747.	2.2	18
106	Prognosis and monitoring of giant cell arteritis and associated complications. Expert Review of Clinical Immunology, 2018, 14, 379-388.	3.0	18
107	Smoking as a risk factor for giant cell arteritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2018, 48, 529-537.	3.4	18
108	Concomitant giant cell aortitis, thoracic aortic aneurysm, and aortic arch syndrome: Occurrence in a patient and significance. Arthritis and Rheumatism, 2003, 49, 858-861.	6.7	17

#	Article	IF	Citations
109	Toward a broader understanding of aldosterone in congestive heart failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 155-163.	1.7	17
110	Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clinical and Experimental Immunology, 2006, 146, 371-380.	2.6	17
111	Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature. Autoimmunity Reviews, 2019, 18, 399-405.	5.8	17
112	Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: A systematic review and meta-analysis. Autoimmunity Reviews, 2020, 19, 102688.	5.8	17
113	Serum S100 Proteins as a Marker of Disease Activity in Large Vessel Vasculitis. Journal of Clinical Rheumatology, 2018, 24, 393-395.	0.9	16
114	Cardiovascular Risk Factors and Atherosclerotic Cardiovascular Events Among Incident Cases of Systemic Sclerosis: Results From a Population-Based Cohort (1980-2016). Mayo Clinic Proceedings, 2020, 95, 1369-1378.	3.0	16
115	Disease progression of Takayasu arteritis in two patients treated with tocilizumab. Annals of the Rheumatic Diseases, 2020, 79, e21-e21.	0.9	15
116	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <scp>Pharmacogenomicsâ€Driven</scp> Machine Learning Approach. Arthritis Care and Research, 2022, 74, 879-888.	3.4	15
117	Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study. Rheumatology, 2010, 49, 2104-2108.	1.9	14
118	Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. Arthritis Research and Therapy, 2022, 24, .	3.5	14
119	Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events. Journal of Rheumatology, 2020, 47, 518-523.	2.0	13
120	Inflammatory Abdominal Aortic Aneurysm. Vascular and Endovascular Surgery, 2014, 48, 65-69.	0.7	12
121	Polymyalgia rheumatica and risk of coronary artery disease: a systematic review and meta-analysis of observational studies. Rheumatology International, 2017, 37, 143-149.	3.0	12
122	Clinical and Radiographic Features of Giant Cell Arteritis With Intracranial Involvement. ACR Open Rheumatology, 2020, 2, 471-477.	2.1	12
123	Beyond Giant Cell Arteritis and Takayasuâ€™s Arteritis: Secondary Large Vessel Vasculitis and Vasculitis Mimickers. Current Rheumatology Reports, 2020, 22, 88.	4.7	12
124	My Treatment Approach to Giant Cell Arteritis. Mayo Clinic Proceedings, 2021, 96, 1530-1545.	3.0	12
125	Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. Arthritis Research and Therapy, 2022, 24, .	3.5	12
126	Prevalence of Takayasu Arteritis: A Population-based Study. Journal of Rheumatology, 2021, 48, 952-952.	2.0	11

#	Article	IF	Citations
127	Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study. Journal of Rheumatology, 2017, 44, 1044-1050.	2.0	11
128	Chronic natural killerâ€“cell lymphocytosis successfully treated with alemtuzumab. Blood, 2009, 114, 3500-3502.	1.4	10
129	Vasculitis working group: Selected unanswered questions related to giant cell arteritis and anti-neutrophil cytoplasmic antibody-associated vasculitis. Joint Bone Spine, 2009, 76, 440-443.	1.6	10
130	Cardiovascular risk factors and acute-phase response in idiopathic ascending aortitis: a case control study. Arthritis Research and Therapy, 2009, 11, R29.	3.5	10
131	Hospitalized Infections in Giant Cell Arteritis â€" A Population-based Retrospective Cohort Study. Journal of Rheumatology, 2014, 41, 2447-2451.	2.0	10
132	Giant cell arteritis and its mimics: A comparison of three patient cohorts. Seminars in Arthritis and Rheumatism, 2020, 50, 923-929.	3.4	10
133	Regulatory T Cells in Autoimmune Vasculitis. Frontiers in Immunology, 2022, 13, 844300.	4.8	10
134	Exercise Echocardiography in Rheumatoid Arthritis: A Case-Control Study. Journal of the American Society of Echocardiography, 2009, 22, 1228-1231.	2.8	9
135	Multicentric Reticulohistiocytosis Can Mimic Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 780-781.	2.0	9
136	Vasculitis of the mesenteric circulation. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 85-96.	2.4	9
137	Morbidity and Mortality of Large-Vessel Vasculitides. Current Rheumatology Reports, 2020, 22, 86.	4.7	9
138	Increased Risk of Valvular Heart Disease in Systemic Sclerosis: An Underrecognized Cardiac Complication. Journal of Rheumatology, 2021, 48, 1047-1052.	2.0	9
139	Lower body mass index is associated with a higher risk of giant cell arteritis: a systematic review and meta-analysis. Annals of Translational Medicine, 2015, 3, 232.	1.7	9
140	Pleuritis and Pericarditis in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Chest, 2021, 160, 572-581.	0.8	8
141	Vacuoles, <scp>E1</scp> enzyme, Xâ€linked, autoinflammatory, somatic (<scp>VEXAS</scp>) syndrome: a presentation of two cases with dermatologic findings. International Journal of Dermatology, 2023, 62, .	1.0	8
142	A 60â€yearâ€old woman with headache, confusion, and hallucinations. Arthritis Care and Research, 2011, 63, 1486-1494.	3.4	7
143	CT angiographic imaging characteristics of thoracic idiopathic aortitis. Journal of Cardiovascular Computed Tomography, 2013, 7, 297-302.	1.3	7
144	Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort. Seminars in Arthritis and Rheumatism, 2021, 51, 1193-1199.	3.4	7

#	Article	IF	Citations
145	Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study. Blood, 2021, 138, 2608-2608.	1.4	7
146	Acute myeloid leukemia associated with necrotizing temporal arteritis. Journal of Rheumatology, 2003, 30, 846-8.	2.0	7
147	Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis. Arthritis and Rheumatism, 2004, 50, 2713-2715.	6.7	6
148	Lack of association of high body mass index with risk for developing polymyalgia rheumatica. International Journal of Rheumatic Diseases, 2010, 13, e1-5.	1.9	6
149	Pulmonary IgG4â€related disease and colon adenocarcinoma: possible paraneoplastic syndrome. International Journal of Rheumatic Diseases, 2017, 20, 654-656.	1.9	6
150	Hospitalization Rates Are Highest in the First 5 Years of Systemic Sclerosis: Results From a Population-based Cohort (1980â€“2016). Journal of Rheumatology, 2021, 48, 877-882.	2.0	6
151	Avacopan â€” Time to Replace Glucocorticoids?. New England Journal of Medicine, 2021, 384, 664-665.	27.0	6
152	Anti-tumor necrosis factor Î± therapy in rheumatoid arthritis: Hitting two birds with one stone?. Arthritis and Rheumatism, 2004, 51, 309-310.	6.7	5
153	Population-based Rate and Patterns of Diplopia in Giant Cell Arteritis. Neuro-Ophthalmology, 2022, 46, 75-79.	1.0	5
154	Recent advances in understanding and treating vasculitis. F1000Research, 2016, 5, 1436.	1.6	4
155	Update on the Epidemiology and Treatment of Giant Cell Arteritis. Current Treatment Options in Rheumatology, 2016, 2, 138-152.	1.4	4
156	Giant cell arteritis associated with inflammatory bowel disease: a case-series and review of the literature. Rheumatology International, 2021, 41, 487-492.	3.0	4
157	Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Noninflammatory Aortic Aneurysms. Arthritis and Rheumatology, 2022, 74, 1376-1386.	5.6	4
158	Treatment Guidelines in Vasculitis. Rheumatic Disease Clinics of North America, 2022, 48, 705-724.	1.9	4
159	A 61â€yearâ€old man with livedo reticularis. Arthritis and Rheumatism, 2008, 59, 1682-1684.	6.7	3
160	Images in vascular medicine. Vascular Medicine, 2010, 15, 135-136.	1.5	3
161	Scalp necrosis in giant cell arteritis after initiation of therapeutic corticosteroids. Journal of the American Academy of Dermatology, 2010, 63, 343-344.	1.2	3
162	A case of refractory rheumatoid pericarditis. Arthritis Care and Research, 2012, 64, 935-940.	3.4	3

#	Article	IF	Citations
163	Isolated Thoracic Aortic Takayasu Arteritis Presenting as Presumed Mobile Aortic Thrombus. Vascular and Endovascular Surgery, 2019, 53, 267-270.	0.7	3
164	Application of the 3â€² mRNA-Seq using unique molecular identifiers in highly degraded RNA derived from formalin-fixed, paraffin-embedded tissue. BMC Genomics, 2021, 22, 759.	2.8	3
165	Cardiopulmonary involvement in Takayasu's arteritis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 46-50.	0.8	3
166	Is Routine Imaging of the Aorta Warranted in Patients With Giant Cell Arteritis?. Journal of Neuro-Ophthalmology, 2017, 37, 314-319.	0.8	2
167	Discordance Rate Among Bilateral Simultaneous and Sequential Temporal Artery Biopsies in Giant Cell Arteritis. JAMA Ophthalmology, 2021, 139, 406.	2.5	2
168	Systemic sclerosis portends increased risk of conduction and rhythm abnormalities at diagnosis and during disease course: A US population-based cohort. Journal of Scleroderma and Related Disorders, 2021, 6, 277-285.	1.7	2
169	A novel humanized model of rheumatoid arthritis associated lung disease. Clinical Immunology, 2021, 230, 108813.	3.2	2
170	Comment on: Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). Rheumatology, 2021, 60, e218-e219.	1.9	2
171	Hypothyroidism in vasculitis. Rheumatology, 2022, 61, 2942-2950.	1.9	2
172	Occurrence and aetiology of gastrointestinal perforation in patients with vasculitis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 32-39.	0.8	2
173	ACR and EULAR bring AAV classification into the twenty-first century. Nature Reviews Rheumatology, 2022, 18, 309-310.	8.0	2
174	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. Interactive Journal of Medical Research, 2022, 11, e27273.	1.4	2
175	61-Year-Old Man With Dyspnea and Bilateral Foot Drop. Mayo Clinic Proceedings, 2002, 77, 363-366.	3.0	1
176	The Nails Give It Away. Journal of the American College of Cardiology, 2011, 57, 996.	2.8	1
177	Impact of Medical Therapy on Late Morbidity and Mortality After Aortic Aneurysm Repair for Aortitis. Annals of Thoracic Surgery, 2018, 105, 1731-1736.	1.3	1
178	Type II cryoglobulinemic vasculitis in the setting of MALT lymphoma. BMJ Case Reports, 2021, 14, e236267.	0.5	1
179	Personalized medicine for the vasculitis patient: hope for the future?. International Journal of Clinical Rheumatology, 2009, 4, 127-132.	0.3	1
180	Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 79-83.	0.8	1

#	Article	IF	Citations
181	Comment on: Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment by Naderi. Clinical and Experimental Rheumatology, 2021, 39, 198-198.	0.8	1
182	Smoldering giant cell arteritis in a coronary artery. Rheumatology, 2022, 61, e384-e385.	1.9	1
183	Vasculitis: Giant Cell Arteritis. , 2013, , 211-224.		0
184	Tocilizumab â€" a new frontier for GCA therapy. Nature Reviews Rheumatology, 2017, 13, 700-701.	8.0	0
185	Reply. Arthritis and Rheumatology, 2019, 71, 1769-1770.	5.6	0
186	Reply. Arthritis and Rheumatology, 2020, 72, 1776-1776.	5.6	0
187	18F-fluorodeoxyglucose positron emission tomography/ computed tomography of giant cell arteritis with lower extremity involvement in association with polymyalgia rheumatica. World Journal of Nuclear Medicine, 2021, 20, 90.	0.5	0
188	Isolated Gastrointestinal Vasculitis. Rare Diseases of the Immune System, 2021, , 211-223.	0.1	0
189	Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply. Rheumatology, 2021, 60, e262-e263.	1.9	0
190	Classification Criteria, Epidemiology and Genetics; and Pathogenesis. Rare Diseases of the Immune System, 2021, , 83-92.	0.1	0
191	Histopathologic Characterization of Vexas Syndrome. Blood, 2021, 138, 4656-4656.	1.4	0
192	In Replyâ€"Giant Cell Arteritis: The Place of 18F-FDG PET/CT and Serum Haptoglobin Level. Mayo Clinic Proceedings, 2022, 97, 190.	3.0	0
193	A call for uniformity in reporting patient level details during description of ophthalmologic major relapse among giant cell arteritis studies. A comment on article by Aussedat M et al. â€œEpidemiology of major relapse in giant cell arteritis: A study-level meta-analysisâ€• Autoimmunity Reviews, 2022, 21, 103062.	5.8	0
194	A primer on vasculitis. Minnesota Medicine, 2013, 96, 36-9.	0.1	0
195	Comment on: Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment by Naderi. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 198.	0.8	0
196	Incidence, prevalence and mortality of chronic periaortitis: a population-based study. Clinical and Experimental Rheumatology, 0, , .	0.8	0
197	Incidence, prevalence and mortality of chronic periaortitis: a population-based study.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0